Intensive alternating drug pairs for treatment of high‐risk childhood acute lymphoblastic leukemia. A pediatric oncology group pilot study

Background. To prevent drug resistance, the authors designed a protocol that featured early intensive rotating drug pairs as part of the therapy for acute lymphoblastic leukemia (ALL).

[1]  M. Relling,et al.  Clinical pharmacodynamic studies of high-dose methotrexate in acute lymphocytic leukemia. , 2009, NCI monographs : a publication of the National Cancer Institute.

[2]  Denis R. Miller,et al.  LSA2–L2 protocol treatment of stage IV non‐hodgkin's lymphoma in children with partial and extensive bone marrow involvement , 2006, Cancer.

[3]  F. Behm,et al.  Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. , 1991, The New England journal of medicine.

[4]  J. Shuster,et al.  A pilot study of intermediate‐dose methotrexate and cytosine arabinoside, “Spread‐out” or “Up‐front,” in continuation therapy for childhood non‐T, non‐B acute lymphoblastic leukemia a pediatric oncology group study , 1991, Cancer.

[5]  F. Behm,et al.  Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy , 1991, The Lancet.

[6]  J. Shuster,et al.  Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: a Pediatric Oncology Group study. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Borowitz,et al.  Prognostic importance of the pre-B-cell immunophenotype and other presenting features in B-lineage childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study. , 1989, Blood.

[8]  H. Sather,et al.  INTENSIVE THERAPY FOR CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKAEMIA AND UNFAVOURABLE PRESENTING FEATURES Early Conclusions of Study CCG-106 by the Childrens Cancer Study Group , 1988, The Lancet.

[9]  R. D. De Abreu,et al.  Effects of methotrexate on purine and pyrimidine metabolism and cell-kinetic parameters in human malignant lymphoblasts of different lineages. , 1988, Biochemical pharmacology.

[10]  F. Behm,et al.  Clinical and biologic hallmarks of the Philadelphia chromosome in childhood acute lymphoblastic leukemia. , 1987, Blood.

[11]  A. Look,et al.  Teniposide plus cytarabine improves outcome in childhood acute lymphoblastic leukemia presenting with a leukocyte count greater than or equal to 100 x 10(9)/L. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Gelber,et al.  Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. , 1986, The New England journal of medicine.

[13]  A. Look,et al.  Chromosomal translocations play a unique role in influencing prognosis in childhood acute lymphoblastic leukemia. , 1986, Blood.

[14]  B. Camitta,et al.  Treatment of refractory acute lymphoblastic leukemia with teniposide and cytarabine. , 1986, Cancer treatment reports.

[15]  A. Bleyer,et al.  Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York regimen--a new intensive therapy protocol: a report from the Childrens Cancer Study Group. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  S L George,et al.  Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. , 1986, The New England journal of medicine.

[17]  K. Bhalla,et al.  Isolation and characterization of an anthracycline-resistant human leukemic cell line. , 1985, Cancer research.

[18]  F. Balis,et al.  Phase I and clinical pharmacological study of mercaptopurine administered as a prolonged intravenous infusion. , 1985, Cancer research.

[19]  T. Necheles,et al.  Comparison of intermediate-dose methotrexate with cranial irradiation for the post-induction treatment of acute lymphocytic leukemia in children. , 1983, The New England journal of medicine.

[20]  P. Wilkinson,et al.  Pharmacologic Principles of Cancer Treatment , 1983, British Journal of Cancer.

[21]  K. Starling,et al.  Modified LSA2-L2 treatment in 53 children with E-rosette-positive T-cell leukemia: results and prognostic factors (a Pediatric Oncology Group Study). , 1982, Blood.

[22]  M. Cooper,et al.  Southwest Oncology Group experience with immunological phenotyping in acute lymphocytic leukemia of childhood. , 1981, Cancer research.

[23]  H. Preisler,et al.  Treatment of Refractory Adult Acute Lymphocytic Leukaemia and Acute Undifferentiated Leukaemia with an Anthracycline Antibiotic and Cytosine Arabinoside , 1981, British journal of haematology.

[24]  R. Aur,et al.  VM‐26 and cytosine arabinoside combination chemotherapy for initial induction failures in childhood lymphocytic leukemia , 1980, Cancer.

[25]  D. Rosenthal,et al.  Treatment of acute myelogenous leukemia in children and adults. , 1980, The New England journal of medicine.

[26]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[27]  S. Shapiro,et al.  ABO BLOOD TYPES IN CONGENITAL HEART-DISEASE , 1975, The Lancet.

[28]  F. Boulton,et al.  NEONATAL COAGULATION , 1975, The Lancet.

[29]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[30]  G. Henze,et al.  Results and significance of six randomized trials in four consecutive ALL-BFM studies. , 1990, Haematology and blood transfusion.

[31]  W. Bleyer,et al.  Biology and pathogenesis of CNS leukemia. , 1989, The American journal of pediatric hematology/oncology.

[32]  Bleyer Wa.  Remaining problems in the staging and treatment of childhood lymphoblastic leukemia. , 1989 .

[33]  W. Bleyer.  Remaining problems in the staging and treatment of childhood lymphoblastic leukemia. , 1989, American Journal Of Pediatric Hematology/Oncology.

[34]  H. Sather,et al.  Modified BFM therapy for children with previously untreated acute lymphoblastic leukemia and unfavorable prognostic features. Report of Children's Cancer Study Group Study CCG-193P. , 1988, The American journal of pediatric hematology/oncology.

[35]  Rivera Gk,et al.  Controversies in the management of childhood acute lymphoblastic leukemia: treatment intensification, CNS leukemia, and prognostic factors , 1987 .

[36]  I. Pastan,et al.  Expression of a multidrug-resistance gene in human tumors and tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[37]  G. Rivera,et al.  Controversies in the management of childhood acute lymphoblastic leukemia: treatment intensification, CNS leukemia, and prognostic factors. , 1987, Seminars in hematology.

[38]  J. Pullen,et al.  Clinical and biologic features predict poor prognosis in acute lymphoid leukemias in children and adolescents: a Pediatric Oncology Group review. , 1986, Medical and pediatric oncology.

[39]  J H Goldie,et al.  Rationale for the use of alternating non-cross-resistant chemotherapy. , 1982, Cancer treatment reports.